Syndax banks an $80M crossover round for PhIII cancer drug

John Carroll Two months after signing up AstraZeneca R&D leader Briggs Morrison as its new CEO, Waltham, MA-based Syndax has raised $ 80 million from a syndicate that includes ...

Novo heralds promising PhIII diabetes data for once-weekly semaglutide

John Carroll Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug–a key ...

Melinta grabs $67M in pursuit of a big PhIII antibiotics finish, NDA

John Carroll A few months after raising $ 357 million to back their new biotech investment group, the ex-Elan team at Malin Corp. has helped place a $ 67 million bet on Melinta Therapeutics, ...

Symbiomix pops out of stealth mode with $41M and a looming PhIII

John Carroll In the little more than two years since its launch, Symbiomix Therapeutics has successfully navigated a midstage study for a sole-asset antibiotic, positioning it for a ...

AbbVie, Neurocrine report a PhIII win for blockbuster contender elagolix

John Carroll AbbVie investigators delivered a fresh set up promising results for a key late-stage drug in the pipeline. In the first of two Phase III studies, the company reports that ...

Novartis’ bid to widen Afinitor’s breast cancer reach falls short in PhIII

Carly Helfand Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod ...

Novartis psoriasis prospect tops J&J’s fast-growing Stelara in PhIII

Carly Helfand J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested ...

Threshold shares surge as PhIII cancer program enters FDA’s fast track

John Carroll Shares of Threshold Pharmaceuticals jumped about 10% this morning on news that the FDA is granting fast-track status to TH-302, the company’s sole therapy now in ...

Shire’s tax model under scrutiny, KDEV cozies up to Asian conglomerate, Onxeo heads to PhIII

Nick Paul Taylor In this week's EuroBiotech Report, after a brief post-AbbVie deal lull in discussion of Shire's tax rate, the Irish-headquartered drugmaker found its financial ...

Amgen’s trebananib flunks key survival measure in ovarian cancer PhIII

John Carroll Amgen reported today that its late-stage cancer drug trebananib missed the goal on a significant improvement for overall survival among patients suffering from platinum-resistant ...

UPDATED: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies

John Carroll Nymox Pharmaceutical is headed for a bruising opening this morning after putting out word on Sunday that both their late-stage studies of their lead drug flopped as a treatment ...

Amgen declares a head-to-head PhIII win for Humira biosimilar

John Carroll Amgen has taken a big stride toward gaining regulatory approval for its biosimilar of Humira, AbbVie's megablockbuster anti-inflammatory. The Big Biotech ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS